| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/15/2005 | EP1539754A2 Benzimidazole quinolinones and uses thereof |
| 06/15/2005 | EP1539753A2 Pyrazolo(3,4-b)pyridine compounds, and their use as phosphodiesterase inhibitors |
| 06/15/2005 | EP1539752A1 Preparation of 1h-imidazo 4,5-c quinolin-4-amines via novel 1h-imidazo 4,5-c quinolin-4-cyano and 1h-imida zo 4,5-c quinolin-4-carboxamide intermediates |
| 06/15/2005 | EP1539751A1 Process for the preparation of imidazo(1,2-a)pyridine-3-acetamides |
| 06/15/2005 | EP1539749A2 Fused heterobicyclo substituted phenyl metabotropic glutamate-5 modulators |
| 06/15/2005 | EP1539748A1 2-phenylpyridin-4-yl derivatives as alk5 inhibitors |
| 06/15/2005 | EP1539746A1 N-substituted-1h-indol-5-propionic acid compounds as ppar agonists useful for the treatment of diabetes |
| 06/15/2005 | EP1539745A1 N-aryl-2-oxazolidinones and their derivatives |
| 06/15/2005 | EP1539744A2 N-hydroxyamide derivatives possessing antibacterial activity |
| 06/15/2005 | EP1539743A1 Pyrazole derivatives as gnrh inhibitors |
| 06/15/2005 | EP1539742A1 Indole derivatives useful as histamine h3 antagonists |
| 06/15/2005 | EP1539741A1 2-thio-substituted imidazole derivatives and their use in pharmaceutics |
| 06/15/2005 | EP1539739A1 Piperidinyl compounds that selectively bind integrins |
| 06/15/2005 | EP1539738A1 Novel aryl- 4-halo-4- heteroarylmethylamino)-methyl]-piperidin-1-yl -methanone derivatives, methods for production and use thereof as medicaments |
| 06/15/2005 | EP1539735A1 Piperazine urea derivatives as melanocortin-4 receptor agonists |
| 06/15/2005 | EP1539732A1 Novel compounds |
| 06/15/2005 | EP1539730A1 Novel compunds, pharmaceutical compositions containing same, and methods of use for same |
| 06/15/2005 | EP1539729A2 Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use |
| 06/15/2005 | EP1539727A2 Compounds, compositions, and methods |
| 06/15/2005 | EP1539725A1 3-(3,5-disubstituted-4-hydroxyphenyl)propionamide derivatives as cathepsin b inhibitors |
| 06/15/2005 | EP1539723A1 Novel use of benzothiazole derivatives |
| 06/15/2005 | EP1539718A1 1,2,4-triazole derivative, method for preparing the same, and pharmaceutical composition containing the same |
| 06/15/2005 | EP1539715A1 Crystal forms of quinoxaline-2-carboxylic acid 4-carbamoyl- 1-(3-fluorobenzyl)-2,7-dihydroxy-7-methyl-octyl -amide |
| 06/15/2005 | EP1539714A2 8-hydroxy-1-oxo-tetrahydropyrrolopyrazine compounds useful as hiv integrase inhibitors |
| 06/15/2005 | EP1539708A1 Benzimidazolones and their use as cytokine inhibitors |
| 06/15/2005 | EP1539707A1 Method and compounds for promoting healing and reducing inflammation |
| 06/15/2005 | EP1539701A1 Caspase inhibitors and uses thereof |
| 06/15/2005 | EP1539700A1 8-hydroxy quinoline derivatives |
| 06/15/2005 | EP1539699A1 4- 7'-halo-2-quino (xa-) linyloxy!phenoxy-propionic acid derivatives as antineoplastic agents |
| 06/15/2005 | EP1539697A1 Phosphodiesterase 4 inhibitors, including n-substituted aniline and diphenylamine analogs |
| 06/15/2005 | EP1539696A2 Process for preparing quinolin antibiotic intermediates |
| 06/15/2005 | EP1539695A1 N-4-piperidinyl compounds as ccr5 modulators |
| 06/15/2005 | EP1539694A1 2,3-dihydro-isoindol-1-ones with mao-b inhibiting activity |
| 06/15/2005 | EP1539693A1 Cannabinoid receptor agonists |
| 06/15/2005 | EP1539691A2 Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases |
| 06/15/2005 | EP1539689A2 Antisense modulation of endothelial lipase expression |
| 06/15/2005 | EP1539687A1 Substituted glycine derivatives for use as medicaments |
| 06/15/2005 | EP1539686A1 Inhibitors of factor xa and other serine proteases involved in the coagulation cascade |
| 06/15/2005 | EP1539685A1 Mcp-1 receptor antagonists and method of use thereof |
| 06/15/2005 | EP1539683A2 Phenol derivatives and their use as rotamase inhibitors |
| 06/15/2005 | EP1539679A2 Oxime and/or hydrazone containing nitrosated and/or nitrosylated cyclooxigenase-2 selective inhibitors, compositions and methods of use |
| 06/15/2005 | EP1539678A1 3,4-di-substituted cyclobutene-1, 2-diones as cxc-chemokine receptor ligands |
| 06/15/2005 | EP1539674A1 Amino-propanol derivatives |
| 06/15/2005 | EP1539672A1 Preparation method of valienamine from acarbose and/or acarbose derivatives using trifluoroacetic acid |
| 06/15/2005 | EP1539664A1 Crystallization of polyol compositions, crystalline polyol composition product and use thereof |
| 06/15/2005 | EP1539662A1 Cannabinoid receptor ligands |
| 06/15/2005 | EP1539284A2 Liquid aerosol formulations and aerosol generating devices and methods for generating aerosols |
| 06/15/2005 | EP1539270A1 Controllable drug releasing gradient coatings for medical devices |
| 06/15/2005 | EP1539250A1 Radioactively labelled amino acid analogues, their preparation and use |
| 06/15/2005 | EP1539248A2 INHIBITORS OF THE S100-p53 PROTEIN-PROTEIN INTERACTION AND METHOD OF INHIBITING CANCER EMPLOYING THE SAME |
| 06/15/2005 | EP1539247A2 Alpha 5 beta 1 and its ability to regulate the cell survival pathway |
| 06/15/2005 | EP1539245A2 Methods and materials for treating human papillomavirus infections |
| 06/15/2005 | EP1539242A2 A composition and method to augment and sustain neurotransmitter production |
| 06/15/2005 | EP1539241A2 Method of controlling pharmacokinetics of immunomodulatory compounds |
| 06/15/2005 | EP1539240A2 Methods and compositions for treating t cell mediated inflammatory/autoimmune diseases and disorders in subjects having a glucocorticoid regulation deficiency |
| 06/15/2005 | EP1539227A2 Papaine containing pharmaceutical formulation resp. its use |
| 06/15/2005 | EP1539225A2 Apparatus and methods for enzymatic escharotomy in burn induced compartment syndrome |
| 06/15/2005 | EP1539219A2 Affinity small molecules for the epo receptor |
| 06/15/2005 | EP1539208A2 Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds |
| 06/15/2005 | EP1539207A1 Treatment of cell proliferative disorders with chlorotoxin |
| 06/15/2005 | EP1539203A1 Echinacea angustifolia extracts |
| 06/15/2005 | EP1539202A1 Method for cancer therapy using herbal extracts |
| 06/15/2005 | EP1539196A1 Vitreoretinal tamponades based on fluorosilicone fluids |
| 06/15/2005 | EP1539195A2 Use of prebiotics for the treatment and prevention of hyperglycaemic syndromes |
| 06/15/2005 | EP1539193A1 Compositions of hyaluronic acid and methods of use |
| 06/15/2005 | EP1539192A1 Composition and kit for the treatment of inflammatory bowel diseases |
| 06/15/2005 | EP1539191A1 Glycoalkaloid compositions and various uses thereof |
| 06/15/2005 | EP1539189A2 Method of using anti-apoptotic factors in gene expression |
| 06/15/2005 | EP1539188A2 Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
| 06/15/2005 | EP1539186A1 Combination therapy comprising a bisphosphonate and a hmg-coa reductase inhibitor |
| 06/15/2005 | EP1539185A2 Methods and compositions for stimulating bone growth using nitric oxide releasing bisphosphonate conjugates (no-bisphosphonate) |
| 06/15/2005 | EP1539184A1 Estrogen replacement regimen |
| 06/15/2005 | EP1539183A1 Therapeutic treatment methods |
| 06/15/2005 | EP1539182A1 Use of anecortave acetate for the protection of visual acuity in patients with age related macular degeneration |
| 06/15/2005 | EP1539181A2 Method of treating lower urinary tract disorders |
| 06/15/2005 | EP1539180A2 Compounds, compositions, and methods |
| 06/15/2005 | EP1539179A2 Angiogenesis inhibition by cephalotaxine alkaloids, derivatives, compositions and uses thereof |
| 06/15/2005 | EP1539177A2 Compositions and methods for treating heart disease |
| 06/15/2005 | EP1539176A1 Thiazine and oxazine derivatives as mmp-13 inhibitors for treating arthritis |
| 06/15/2005 | EP1539175A2 Substituted indolealkanoic acids derivative and formulations containing same for use in treatment of diabetic complications |
| 06/15/2005 | EP1539174A2 Use of pde iv inhibitors to treat angiogenesis |
| 06/15/2005 | EP1539172A1 New therapeutic uses of (4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl) thieno[2,3-d]pyrimidine |
| 06/15/2005 | EP1539171A2 Use of chymase inhibitors for the prevention and/or treatment of arterio-venous graft failure |
| 06/15/2005 | EP1539170A2 Stabilized formulations of alpha adrenergic receptor antagonists and uses thereof |
| 06/15/2005 | EP1539169A2 Amyotrophic lateral sclerosis treatment with cyclooxygenase-2 inhibitors |
| 06/15/2005 | EP1539168A2 Treatment of neuropathic pain with 6h-pyrrolo(3,4-d)pyridazine compounds |
| 06/15/2005 | EP1539167A2 Ciprofloxacin hci |
| 06/15/2005 | EP1539166A1 Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders |
| 06/15/2005 | EP1539165A1 Sustained-release tablet composition comprising a dopamine receptor agonist |
| 06/15/2005 | EP1539164A1 2-hydroxy-6-phenylphenanthridines as pde-4 inhibitors |
| 06/15/2005 | EP1539162A1 Method for improving the ability of patients suffering from lung diseases to participate in and benefit from pulmonary rehabilitation programs |
| 06/15/2005 | EP1539161A1 Novel salt and polymorphs of desloratadine hemifumarate |
| 06/15/2005 | EP1539160A1 Piperidin-2,6-dione pamoate salts and their use for the treatment of stress-related affective disorders |
| 06/15/2005 | EP1539157A2 Method of inhibiting choroidal neovascularization |
| 06/15/2005 | EP1539156A1 Liquid dosage forms of acid labile drugs |
| 06/15/2005 | EP1539155A1 Stable cream preparations of phenyl-pyridone compounds for topical application |
| 06/15/2005 | EP1539153A2 Therapeutic treatment for the metabolic syndrome and type 2 diabetes |
| 06/15/2005 | EP1539152A2 Development of muscle mass in a mammal |
| 06/15/2005 | EP1539151A1 Biaryl compounds having anti-infective activity |
| 06/15/2005 | EP1539150A1 Naphthalimide synthesis including amonafide synthesis and pharmaceutical preparations thereof |